A PARADIGM SHIFT IN EARLY DRUG DEVELOPMENT: INDIVIDUALIZING TO MORE PATIENT BENEFIT

What is the feature of an optimal new agent: Selective target versus multi-targeted versus combination drugs

J. Schellens